Your browser doesn't support javascript.
loading
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy.
Dahal, Lekh N; Huang, Chie-Yin; Stopforth, Richard J; Mead, Abbie; Chan, Keith; Bowater, Juliet X; Taylor, Martin C; Narang, Priyanka; Chan, H T Claude; Kim, Jinny H; Vaughan, Andrew T; Forconi, Francesco; Beers, Stephen A.
Afiliação
  • Dahal LN; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Huang CY; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Stopforth RJ; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Mead A; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Chan K; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Bowater JX; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Taylor MC; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Narang P; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Chan HTC; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Kim JH; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Vaughan AT; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and.
  • Forconi F; Cancer Sciences Unit, Cancer Research UK and National Institute for Health Research Experimental Cancer Medicine Centres, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom.
  • Beers SA; Antibody and Vaccine Group, Centre for Cancer Immunology, Faculty of Medicine, University of Southampton, Southampton General Hospital, Southampton SO16 6YD, United Kingdom; and sab@soton.ac.uk.
J Immunol ; 201(4): 1211-1221, 2018 08 15.
Article em En | MEDLINE | ID: mdl-29997125
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fagocitose / Modulação Antigênica / Resistencia a Medicamentos Antineoplásicos / Antígenos CD20 / Anticorpos Monoclonais Humanizados / Rituximab Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fagocitose / Modulação Antigênica / Resistencia a Medicamentos Antineoplásicos / Antígenos CD20 / Anticorpos Monoclonais Humanizados / Rituximab Limite: Animals / Humans Idioma: En Ano de publicação: 2018 Tipo de documento: Article